Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
29.33
+1.46 (5.24%)
At close: May 12, 2025, 4:00 PM
28.00
-1.33 (-4.53%)
After-hours: May 12, 2025, 6:20 PM EDT
Avidity Biosciences Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Avidity Biosciences stock have an average target of 67.92, with a low estimate of 53 and a high estimate of 96. The average target predicts an increase of 131.57% from the current stock price of 29.33.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Avidity Biosciences stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 5 | 4 | 4 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $72 → $68 | Strong Buy | Maintains | $72 → $68 | +131.84% | May 12, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $65 | Strong Buy | Maintains | $65 | +121.62% | May 9, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $65 | Strong Buy | Maintains | $65 | +121.62% | May 7, 2025 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +104.57% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +145.48% | Mar 18, 2025 |
Financial Forecast
Revenue This Year
6.82M
from 10.90M
Decreased by -37.39%
Revenue Next Year
15.11M
from 6.82M
Increased by 121.50%
EPS This Year
-3.94
from -2.89
EPS Next Year
-4.48
from -3.94
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 22.1M | 81.6M | 770.0M | ||
| Avg | 6.8M | 15.1M | 310.0M | ||
| Low | n/a | n/a | 78.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 102.3% | 1,095.7% | 4,994.8% | ||
| Avg | -37.4% | 121.5% | 1,951.5% | ||
| Low | - | - | 418.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.50 | -2.46 | -0.39 | ||
| Avg | -3.94 | -4.48 | -2.85 | ||
| Low | -4.89 | -5.65 | -5.04 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.